CA2909919C - Formulation de produit de contraste et son procede de preparation associe - Google Patents

Formulation de produit de contraste et son procede de preparation associe Download PDF

Info

Publication number
CA2909919C
CA2909919C CA2909919A CA2909919A CA2909919C CA 2909919 C CA2909919 C CA 2909919C CA 2909919 A CA2909919 A CA 2909919A CA 2909919 A CA2909919 A CA 2909919A CA 2909919 C CA2909919 C CA 2909919C
Authority
CA
Canada
Prior art keywords
complex
dota
composition
composition according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909919A
Other languages
English (en)
French (fr)
Other versions
CA2909919A1 (fr
Inventor
Christelle Medina
Monique SABATOU
Anne PETIT
Marc Port
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48856855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2909919(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Guerbet SA filed Critical Guerbet SA
Publication of CA2909919A1 publication Critical patent/CA2909919A1/fr
Application granted granted Critical
Publication of CA2909919C publication Critical patent/CA2909919C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
CA2909919A 2013-04-26 2014-04-28 Formulation de produit de contraste et son procede de preparation associe Active CA2909919C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1353883 2013-04-26
FR1353883 2013-04-26
PCT/EP2014/058617 WO2014174120A1 (fr) 2013-04-26 2014-04-28 Formulation de produit de contraste et son procede de preparation associe

Publications (2)

Publication Number Publication Date
CA2909919A1 CA2909919A1 (fr) 2014-10-30
CA2909919C true CA2909919C (fr) 2022-07-12

Family

ID=48856855

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909919A Active CA2909919C (fr) 2013-04-26 2014-04-28 Formulation de produit de contraste et son procede de preparation associe

Country Status (14)

Country Link
US (1) US10918743B2 (https=)
EP (1) EP2988756B2 (https=)
JP (1) JP6608805B2 (https=)
KR (1) KR102231121B1 (https=)
CN (2) CN116173247A (https=)
BR (1) BR112015026473B1 (https=)
CA (1) CA2909919C (https=)
DK (1) DK2988756T4 (https=)
ES (1) ES2626582T5 (https=)
HR (1) HRP20170874T4 (https=)
HU (1) HUE033219T2 (https=)
PL (1) PL2988756T5 (https=)
PT (1) PT2988756T (https=)
WO (1) WO2014174120A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
RU2769699C2 (ru) * 2016-12-21 2022-04-05 ДжиИ Хелткер АС Хелатные соединения марганца на основе тетраазабицикло-макроцикла, подходящие в качестве визуализирующих агентов для MRI
EP3728168B1 (en) 2017-12-20 2022-03-30 General Electric Company Anionic chelate compounds
EP4491199A3 (en) 2018-08-06 2025-04-16 Bracco Imaging SPA Gadolinium bearing pcta-based contrast agents
CN113164628A (zh) 2018-11-23 2021-07-23 拜耳股份有限公司 造影介质制剂及其制备方法
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
FR3091872B1 (fr) 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
CN116209661B (zh) * 2020-07-17 2026-01-27 法国加栢 用于制备基于pcta的螯合配体的方法
US12409239B2 (en) 2021-06-25 2025-09-09 Beacon Mri Ltd Particles for use in hyperpolarization

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
DE3640708C2 (de) * 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
ATE130518T1 (de) 1987-06-30 1995-12-15 Mallinckrodt Inc Verfahren zur erhöhung der sicherheit von metall- ligandchelaten als röntgenstrahlen- kontrastmittel.
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
GB9001245D0 (en) * 1990-01-19 1990-03-21 Salutar Inc Compounds
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
DE4115789A1 (de) 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
MX9207164A (es) 1991-12-10 1993-07-01 Dow Chemical Co Complejos de acido biciclopoliazamacrociclocarboxilico, sus conjugados, procedimientos para su preparacion y su uso como agentes de contraste.
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
DE19719033C1 (de) 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6559330B1 (en) 1999-09-09 2003-05-06 Schering Aktiengesellschaft Calcium complex of [[(4r)-4-[bis{carboxy-.kappa.o)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.o)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.n6,.kappa.n9,.kappa.011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2927539B1 (fr) 2008-02-19 2010-07-30 Guerbet Sa Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
NO331773B1 (no) 2009-12-18 2012-03-26 Ge Healthcare As Mangankelater, sammensetninger omfattende slike og anvendelse av disse som kontrastmidler for magnettomografi (MR)
EP2554167A1 (en) 2011-08-02 2013-02-06 Bracco Imaging S.p.A New use of l-histidine and derivatives thereof

Also Published As

Publication number Publication date
PL2988756T5 (pl) 2022-09-26
EP2988756B2 (fr) 2022-05-18
PL2988756T3 (pl) 2017-08-31
CN105142649A (zh) 2015-12-09
CN116173247A (zh) 2023-05-30
JP2016521275A (ja) 2016-07-21
ES2626582T5 (es) 2022-10-07
HRP20170874T1 (hr) 2017-09-22
US20160101196A1 (en) 2016-04-14
US10918743B2 (en) 2021-02-16
PT2988756T (pt) 2017-05-08
BR112015026473A2 (pt) 2017-07-25
KR102231121B1 (ko) 2021-03-23
EP2988756B1 (fr) 2017-03-08
KR20160002821A (ko) 2016-01-08
DK2988756T3 (en) 2017-06-26
ES2626582T3 (es) 2017-07-25
JP6608805B2 (ja) 2019-11-20
HUE033219T2 (en) 2017-11-28
EP2988756A1 (fr) 2016-03-02
CA2909919A1 (fr) 2014-10-30
HRP20170874T4 (hr) 2022-09-02
BR112015026473B1 (pt) 2020-12-01
WO2014174120A1 (fr) 2014-10-30
DK2988756T4 (da) 2022-08-08

Similar Documents

Publication Publication Date Title
CA2909919C (fr) Formulation de produit de contraste et son procede de preparation associe
ES2593127T3 (es) Proceso para preparar una formulación farmacéutica de agentes de contraste
JP2022046482A (ja) Ｍｒｉ造影剤の併用を含む製剤
JP2019500333A5 (https=)
US12303573B2 (en) Formulation of contrast media and process of preparation thereof
FR2927539A1 (fr) Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
JPH01259850A (ja) Ｍｎ（ＩＩ）配位組成物を使用するＮＭＲ像形成
JP7801229B2 (ja) Ｍｒｉ用造影剤としての鉄錯体およびその塩
RU2815053C2 (ru) Состав контрастных средств и способ его получения
FR2921271A1 (fr) Formulation d'agents de contraste pour l'irm contenant une polybase organique
BR122025004748A2 (pt) Formulação farmacêutica líquida, tetraquelato derivado de do3a com quantidades sub-estequiométricas de íons gadolínio (gd3+), seu uso, e método de imagem do corpo inteiro de um indivíduo, ou de imagem de uma parte do corpo
EP3192530A1 (fr) Nanoparticules ultrafines comme agent d'imagerie pour el diagnostic d'une dysfonction rénale
BR112021007707B1 (pt) Formulação farmacêutica líquida, e seu processo de preparação

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190404